Company Overview

Hexima is a biotechnology company engaged in the research and development of plant-derived defensin peptides for applications as human therapeutics. Its lead product candidate, pezadeftide applied in a topical formulation, is a potential new prescription treatment for toenail fungal infections (or onychomycosis). Hexima is currently conducting a 132 patient Australian phase IIb clinical trial of pezadeftide for onychomycosis. Hexima holds granted, long-life patents protecting pezadeftide in major markets globally.

Latest News